BR112013023052A2 - métodos para tratar lúpus cutâneo, e um indivíduo, kit, e, uso de um composto - Google Patents
métodos para tratar lúpus cutâneo, e um indivíduo, kit, e, uso de um compostoInfo
- Publication number
- BR112013023052A2 BR112013023052A2 BR112013023052A BR112013023052A BR112013023052A2 BR 112013023052 A2 BR112013023052 A2 BR 112013023052A2 BR 112013023052 A BR112013023052 A BR 112013023052A BR 112013023052 A BR112013023052 A BR 112013023052A BR 112013023052 A2 BR112013023052 A2 BR 112013023052A2
- Authority
- BR
- Brazil
- Prior art keywords
- kit
- individual
- compound
- methods
- cutaneous lupus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451531P | 2011-03-10 | 2011-03-10 | |
| PCT/US2012/028429 WO2012122452A1 (en) | 2011-03-10 | 2012-03-09 | 2,4 substituted pyrimidinediamines for use in discoid lupus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013023052A2 true BR112013023052A2 (pt) | 2017-07-25 |
Family
ID=45922810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013023052A BR112013023052A2 (pt) | 2011-03-10 | 2012-03-09 | métodos para tratar lúpus cutâneo, e um indivíduo, kit, e, uso de um composto |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8497279B2 (pt) |
| EP (1) | EP2683385B1 (pt) |
| JP (1) | JP6121917B2 (pt) |
| KR (1) | KR101802011B1 (pt) |
| CN (1) | CN103533938A (pt) |
| AU (1) | AU2012225367B2 (pt) |
| BR (1) | BR112013023052A2 (pt) |
| CA (1) | CA2866460C (pt) |
| CY (1) | CY1120860T1 (pt) |
| DK (1) | DK2683385T3 (pt) |
| EA (1) | EA030249B1 (pt) |
| ES (1) | ES2686532T3 (pt) |
| HR (1) | HRP20181286T1 (pt) |
| HU (1) | HUE039486T2 (pt) |
| LT (1) | LT2683385T (pt) |
| MX (1) | MX343517B (pt) |
| PL (1) | PL2683385T3 (pt) |
| PT (1) | PT2683385T (pt) |
| RS (1) | RS57672B1 (pt) |
| SI (1) | SI2683385T1 (pt) |
| WO (1) | WO2012122452A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2013086196A1 (en) * | 2011-12-08 | 2013-06-13 | Rigel Pharmaceuticals, Inc. | Topical formulation for administering a compound |
| WO2014043257A1 (en) * | 2012-09-12 | 2014-03-20 | Rigel Pharmaceuticals, Inc. | Treatment for vitiligo |
| CN107805212B (zh) * | 2017-11-03 | 2021-08-20 | 宿迁德威化工股份有限公司 | 一种2-甲基-5-氨基苯磺酰胺的制备方法 |
| WO2021113410A1 (en) * | 2019-12-02 | 2021-06-10 | Ampersand Biopharmaceuticals, Inc. | Transdermal penetrant formulations for vitamins, minerals and supplements |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US296006A (en) | 1884-04-01 | John hoefleb | ||
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| JPS6069037A (ja) | 1983-09-26 | 1985-04-19 | Sunstar Inc | エリテマト−デス治療用外用剤 |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
| ES2445208T3 (es) | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
| US7491732B2 (en) * | 2005-06-08 | 2009-02-17 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US8013120B2 (en) | 2005-10-26 | 2011-09-06 | Stc.Unm | C-reactive protein and its use to treat systemic lupus erythematosus and related conditions |
| WO2007070872A1 (en) | 2005-12-15 | 2007-06-21 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
-
2012
- 2012-03-09 CA CA2866460A patent/CA2866460C/en not_active Expired - Fee Related
- 2012-03-09 LT LTEP12711500.4T patent/LT2683385T/lt unknown
- 2012-03-09 WO PCT/US2012/028429 patent/WO2012122452A1/en active Application Filing
- 2012-03-09 PL PL12711500T patent/PL2683385T3/pl unknown
- 2012-03-09 SI SI201231361T patent/SI2683385T1/sl unknown
- 2012-03-09 DK DK12711500.4T patent/DK2683385T3/en active
- 2012-03-09 EA EA201391304A patent/EA030249B1/ru not_active IP Right Cessation
- 2012-03-09 US US13/416,748 patent/US8497279B2/en active Active
- 2012-03-09 CN CN201280021346.9A patent/CN103533938A/zh active Pending
- 2012-03-09 EP EP12711500.4A patent/EP2683385B1/en active Active
- 2012-03-09 HU HUE12711500A patent/HUE039486T2/hu unknown
- 2012-03-09 JP JP2013557894A patent/JP6121917B2/ja not_active Expired - Fee Related
- 2012-03-09 ES ES12711500.4T patent/ES2686532T3/es active Active
- 2012-03-09 KR KR1020137026550A patent/KR101802011B1/ko active IP Right Grant
- 2012-03-09 MX MX2013010308A patent/MX343517B/es active IP Right Grant
- 2012-03-09 AU AU2012225367A patent/AU2012225367B2/en not_active Ceased
- 2012-03-09 PT PT12711500T patent/PT2683385T/pt unknown
- 2012-03-09 BR BR112013023052A patent/BR112013023052A2/pt not_active Application Discontinuation
- 2012-03-09 RS RS20181046A patent/RS57672B1/sr unknown
-
2013
- 2013-05-30 US US13/906,083 patent/US20130274277A1/en not_active Abandoned
-
2018
- 2018-08-06 HR HRP20181286TT patent/HRP20181286T1/hr unknown
- 2018-09-06 CY CY181100935T patent/CY1120860T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012225367B2 (en) | 2017-05-25 |
| CY1120860T1 (el) | 2019-12-11 |
| US8497279B2 (en) | 2013-07-30 |
| MX2013010308A (es) | 2013-12-02 |
| EP2683385A1 (en) | 2014-01-15 |
| MX343517B (es) | 2016-11-07 |
| PL2683385T3 (pl) | 2018-12-31 |
| CA2866460A1 (en) | 2012-09-13 |
| EA030249B1 (ru) | 2018-07-31 |
| WO2012122452A1 (en) | 2012-09-13 |
| EP2683385B1 (en) | 2018-06-06 |
| KR20140025377A (ko) | 2014-03-04 |
| US20130274277A1 (en) | 2013-10-17 |
| JP2014507480A (ja) | 2014-03-27 |
| RS57672B1 (sr) | 2018-11-30 |
| HRP20181286T1 (hr) | 2018-10-05 |
| KR101802011B1 (ko) | 2017-11-27 |
| DK2683385T3 (en) | 2018-09-17 |
| US20120232106A1 (en) | 2012-09-13 |
| HUE039486T2 (hu) | 2019-01-28 |
| AU2012225367A1 (en) | 2013-10-24 |
| EA201391304A1 (ru) | 2014-05-30 |
| PT2683385T (pt) | 2018-10-19 |
| CN103533938A (zh) | 2014-01-22 |
| CA2866460C (en) | 2021-03-09 |
| LT2683385T (lt) | 2018-10-25 |
| JP6121917B2 (ja) | 2017-04-26 |
| SI2683385T1 (sl) | 2018-11-30 |
| ES2686532T3 (es) | 2018-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014000260A2 (pt) | composto, e, uso de um composto | |
| BR112013018656A2 (pt) | sistemas e métodos para maximização de uso de amostra | |
| BR112013025355A2 (pt) | combinações de compostos de inibidor de akt e abiraterona e métodos de uso | |
| CR20140034A (es) | Métodos para tratar el cáncer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek | |
| BR112014001346A2 (pt) | composto nanotransportador, método, composto farmacêutico e uso de um composto | |
| CO6870033A2 (es) | Compuestos terapéuticos y métodos de uso relacionados | |
| BR112012019936A2 (pt) | uso de um composto, método de preparação de um composto, método e composto | |
| CO6920293A2 (es) | Compuestos antibaterianos y método para su uso | |
| BR112013020611A2 (pt) | método para produção de compostos quelato de aminoácido, compostos quelato de aminoácido e uso de compostos quelato de aminoácido | |
| CO6821883A2 (es) | Nuevos moduladores y métodos para su uso | |
| BR112013013523A2 (pt) | centralizador, método, e, uso de um centralizador | |
| BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
| BR112015005436A2 (pt) | kit de tratamento, dispositivo de tratamento e método para fabricar um dispositivo | |
| BR112014008088A2 (pt) | método para detectar anticorpos, uso de um método, e, kit | |
| BR112013028959A2 (pt) | composto, processo para o preparo de um composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
| BR112014011685A2 (pt) | composto, utilização de um composto e método | |
| BR112013033968A2 (pt) | uso de anticorpos agonistas anti-cd83 para tratamento de doenças autoimunes | |
| BR112013029206A2 (pt) | composto, e, uso de um composto | |
| BR112013022552A2 (pt) | compostos de quinazolina substituídos com alcino e métodos de uso | |
| BR112014009471A2 (pt) | compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
| BR112013034055A2 (pt) | alcaftadina para uso no tratamento de urticária | |
| BR112014016635A8 (pt) | composto, composição, e, uso de um composto | |
| BR112014007641A2 (pt) | uso de um biocida | |
| BR112013006131A2 (pt) | inibidores de notum pectinacetilesterase e métodos para sua utilização | |
| BR112013028901A2 (pt) | uso de um composto, método para identificar um líquido de hidrocarboneto, e, líquido de hidrocarboneto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |